Dyadic International (DYAI) Non Operating Interest Expenses (2024 - 2026)
Dyadic International's (DYAI) quarterly Non Operating Interest Expenses came in at $64342.0 in Q1 2026, down 27.9% year-over-year from $89243.0 in Q1 2025, and down 4.57% quarter-over-quarter from $67421.0 in Q4 2025.
Analysis
Dyadic International (DYAI) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends
Dyadic International has disclosed Non Operating Interest Expenses across 3 years of filings, most recently posting $64342.0 for Q1 2026.
- In Q1 2026, Non Operating Interest Expenses fell 27.9% year-over-year to $64342.0; the TTM figure through Mar 2026 stood at $307153.0 (down 13.66% YoY), while the FY2025 annual figure was $332054.0, up 15.24% from the prior year.
- Non Operating Interest Expenses came in at $64342.0 for Q1 2026 at Dyadic International, down from $67421.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $89456.0 in Q2 2025 to a low of $21639.0 in Q1 2024.
- Average Non Operating Interest Expenses over 3 years is $76059.8, with a median of $88634.0 recorded in 2024.
- Year-over-year, Non Operating Interest Expenses soared 312.42% in 2025 and slipped 27.9% in 2026.
- Over 3 years, Non Operating Interest Expenses stood at $89036.0 in 2024, then dropped by 24.28% to $67421.0 in 2025, then slipped by 4.57% to $64342.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $64342.0 in Q1 2026, $67421.0 in Q4 2025, and $85934.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.35 Bn | 192.36 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.10 Bn | 176.92 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.31 Bn | 123.46 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.77 Bn | 73.78 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.56 Bn | 55.38 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.68 Bn | 48.54 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.44 Bn | 30.14 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.80 Bn | 30.52 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | 64,342.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 64,342.00 |
| Dec 31, 2025 | 67,421.00 |
| Sep 30, 2025 | 85,934.00 |
| Jun 30, 2025 | 89,456.00 |
| Mar 31, 2025 | 89,243.00 |
| Dec 31, 2024 | 89,036.00 |
| Sep 30, 2024 | 88,833.00 |
| Jun 30, 2024 | 88,634.00 |
| Mar 31, 2024 | 21,639.00 |